Podcast

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

Author(s):

Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand access and address financial toxicity.

Welcome to OncLive On Air®! I’m your host today, Jason Harris.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we spoke with Craig Sauter, MD, director of Cleveland Clinic’s Blood and Marrow Transplant Program, and Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and a staff physician at the Cleveland Clinic Taussig Cancer Institute, about the use of CAR T-cell therapy in patients with lymphomas.

Drs Sauter and Hill discussed the findings from the phase 3 ZUMA-7 (NCT03391466) and TRANSFORM (NCT03575351) trials, which suggest that CAR T cells might be more effective in the second-line setting compared with standard treatment. They also considered the potential for allogeneic CAR T cells, new data showing that investigators may be able to cut CAR T development time down to 1 to 2 days, and ways to expand access and address financial toxicity.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.